SK Capital to Invest in Swixx BioPharma in Deal Valued at Over €1.5 Billion

SK Capital affiliate acquires Apotex Pharmaceutical Holdings

April 3, 2023

Pharmaceuticals

An affiliate of funds advised by SK Capital Partners has acquired Apotex Pharmaceutical Holdings Inc. The acquisition closed on April 3, 2023.

SK bioscience Invests $3M in U.S. Biotech Fina Biosolutions

October 8, 2024

Biotechnology

SK bioscience has invested USD 3 million to acquire a stake in Fina Biosolutions (FinaBio), a Rockville, Maryland–based developer of conjugate vaccine technologies and CRM197 protein manufacturing. The strategic investment makes SK bioscience FinaBio's first strategic investor and is intended to accelerate commercialization of FinaBio's EcoCRM and conjugation technologies while enhancing SK bioscience's vaccine development and manufacturing capabilities.

SK Capital Partners Acquires Majority Stake in SEQENS

December 16, 2021

Pharmaceuticals

Funds advised by SK Capital Partners acquired a majority shareholding in SEQENS, investing alongside Bpifrance, Nov Santé, Mérieux Equity Partners, Ardian, Eximium and SEQENS' management. The deal includes the integration of Wavelength Pharmaceuticals into SEQENS and the prior divestiture of certain non-core mineral specialties assets; SEQENS emerges as a strengthened pharmaceutical CDMO with ~€1.1bn revenue and ~3,200 employees.

Sovereign Capital Partners Invests in Bioscript

March 4, 2021

Healthcare Services

Sovereign Capital Partners has completed a significant investment in Bioscript, a Macclesfield-based medical communications and regulatory writing agency, partnering with the management team to accelerate growth. The capital will support service development and geographic expansion as Bioscript looks to grow its UK and international presence.

Nordic Capital and Permira to Acquire Bavarian Nordic for About $3 Billion

July 31, 2025

Biotechnology

Bavarian Nordic A/S has accepted a takeover offer valued at DKK 19 billion (about $2.99 billion) from a consortium of Nordic Capital and Permira. Shareholders will receive an all-cash offer of 233 Danish kroner per share, and the deal is expected to close in the fourth quarter of 2025 subject to regulatory approvals and acceptance conditions.

Paine Schwartz Partners Makes Strategic Investment in Sterilex

April 27, 2021

Manufacturing

Paine Schwartz Partners has made a strategic growth investment through its Food Chain Fund V in Sterilex, a Hunt Valley, Maryland-based developer of proprietary antimicrobial and biofilm-control products serving food processing, animal health and water treatment markets. The investment will support Sterilex's product development, geographic expansion and scaling of its food safety platform; financial terms were not disclosed.